Alex Bokov

Alex Bokov

Auto-generated profile, based on publicly available information

Alex Bokov

Department of Population Health Sciences, University of Texas Health San Antonio, San Antonio, TX, United States

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
VPViviana I. Pérez
Viviana I. Pérez
ABAlex Bokov
Alex Bokov
HRHolly Van Remmen
Holly Van Remmen
JMJames Mele
James Mele
QRQitao Ran
Qitao Ran
ARArlan Richardson
Arlan Richardson

1 October 2004 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
ABAlex Bokov
Alex Bokov
ACAsish Chaudhuri
Asish Chaudhuri
ARArlan Richardson
Arlan Richardson

28 January 2009 in Aging Cell
Verified
Journal Article
Open access
PDF file
VPViviana I. Pérez
Viviana I. Pérez
HRHolly Van Remmen
Holly Van Remmen
ABAlex Bokov
Alex Bokov
CECharles J. Epstein
Charles J. Epstein
JVJan Vijg
Jan Vijg
ARArlan Richardson
Arlan Richardson
Summary: We evaluated the effect of overexpressing antioxidant enzymes on the lifespans of transgenic mice that overexpress copper zinc superoxide dismutase (CuZnSOD), catalase, or combinations of either CuZnSOD and catalase or CuZnSOD and manganese superoxide dismutase (MnSOD). Our results show that the overexpression of these major antioxidant enzymes, which are known to scavenge superoxide and hydrogen peroxide in the cytosolic and mitochondrial compartments, is insufficient to extend lifespan in mice.

7 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WFWilson C. Fok
Wilson C. Fok
YCYidong Chen
Yidong Chen
ABAlex Bokov
Alex Bokov
YZYiqiang Zhang
Yiqiang Zhang
ASAdam Salmon
Adam Salmon
ARArlan Richardson
Arlan Richardson
Rapamycin was found to increase (11% to 16%) the lifespan of male and female C57BL/6J mice most likely by reducing the increase in the hazard for mortality (i.e., the rate of aging) term in the Gompertz mortality analysis. To identify the pathways that could be responsible for rapamycin's longevity effect, we analyzed the transcriptome of liver from 25-month-old male and female mice fed rapamycin starting at 4 months of age. Few changes (4,500) changed significantly in females. Using multidimensional scaling and heatmap analyses, the male mice fed rapamycin were found to segregate into two groups: one group that is almost identical to control males (Rapa-1) and a second group (Rapa-2) that shows a change in gene expression (>4,000 transcripts) with more than 60% of the genes shared with female mice fed Rapa. Using ingenuity pathway analysis, 13 pathways were significantly altered in both Rapa-2 males and rapamycin-fed females with mitochondrial function as the most significantly changed pathway. Our findings show that rapamycin has a major effect on the transcriptome and point to several pathways that would likely impact the longevity.

23 November 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAlex F Bokov
Alex F Bokov
NGNeha Garg
Neha Garg
YIYuji Ikeno
Yuji Ikeno
STSachin Thakur
Sachin Thakur
NMNicolas Musi
Nicolas Musi
ARArlan Richardson
Arlan Richardson
Mutations in insulin/IGF-1 signaling pathway have been shown to lead to increased longevity in various invertebrate models. Therefore, the effect of the haplo- insufficiency of the IGF-1 receptor (Igf1r+/−) on longevity/aging was evaluated in C57Bl/6 mice using rigorous criteria where lifespan and end-of-life pathology were measured under optimal husbandry conditions using large sample sizes. Igf1r+/− mice exhibited reductions in IGF-1 receptor levels and the activation of Akt by IGF-1, with no compensatory increases in serum IGF-1 or tissue IGF-1 mRNA levels, indicating that the Igf1r+/− mice show reduced IGF-1 signaling. Aged male, but not female Igf1r+/− mice were glucose intolerant, and both genders developed insulin resistance as they aged. Female, but not male Igf1r+/− mice survived longer than wild type mice after lethal paraquat and diquat exposure, and female Igf1r+/− mice also exhibited less diquat-induced liver damage. However, no significant difference between the lifespans of the male Igf1r+/− and wild type mice was observed; and the mean lifespan of the Igf1r+/− females was increased only slightly (less than 5%) compared to wild type mice. A comprehensive pathological analysis showed no significant difference in end-of-life pathological lesions between the Igf1r+/− and wild type mice. These data show that the Igf1r+/− mouse is not a model of increased longevity and delayed aging as predicted by invertebrate models with mutations in the insulin/IGF-1 signaling pathway.

1 February 2013 in Aging
Verified
Journal Article
Open access
CLCarolina B. Livi
Carolina B. Livi
RHRulon L. Hardman
Rulon L. Hardman
BCBarbara A. Christy
Barbara A. Christy
SDSherry G. Dodds
Sherry G. Dodds
DJDiane Jones
Diane Jones
ZSZelton Dave Sharp
Zelton Dave Sharp
Chronic treatment of mice with an enterically released formulation of rapamycin (eRapa) extends median and maximum life span, partly by attenuating cancer. The mechanistic basis of this response is not known. To gain a better understanding of thesein vivo effects, we used a defined preclinical model of neuroendocrine cancer, Rb1+/- mice. Previous results showed that diet restriction (DR) had minimal or no effect on the lifespan of Rb1+/- mice, suggesting that the beneficial response to DR is dependent on pRb1. Since long-term eRapa treatment may at least partially mimic chronic DR in lifespan extension, we predicted that it would have a minimal effect in Rb1+/- mice. Beginning at 9 weeks of age until death, we fed Rb1+/- mice a diet without or with eRapa at 14 mg/kg food, which results in an approximate dose of 2.24 mg/kg body weight per day, and yielded rapamycin blood levels of about 4 ng/ml. Surprisingly, we found that eRapa dramatically extended life span of both female and male Rb1+/- mice, and slowed the appearance and growth of pituitary and decreased the incidence of thyroid tumors commonly observed in these mice. In this model, eRapa appears to act differently than DR, suggesting diverse mechanisms of action on survival and anti-tumor effects. In particular the beneficial effects of rapamycin did not depend on the dose of Rb1.